Previous close | 1.4500 |
Open | 1.5000 |
Bid | 0.0000 |
Ask | 1.6000 |
Strike | 6.00 |
Expiry date | 2024-12-20 |
Day's range | 1.5000 - 1.5000 |
Contract range | N/A |
Volume | |
Open interest | 106 |
Helen Thackray, Chief Research & Development Officer of BioCryst Pharmaceuticals Inc (NASDAQ:BCRX), purchased 30,000 shares of the company on May 14, 2024.
On May 13, 2024, Steven Galson, a Director at BioCryst Pharmaceuticals Inc (NASDAQ:BCRX), purchased 21,940 shares of the company, as reported in a recent SEC Filing.
Charles Gayer, Chief Commercial Officer of BioCryst Pharmaceuticals Inc (NASDAQ:BCRX), purchased 30,000 shares of the company on May 13, 2024.